McDonnell NA, et al. - The feasibility and safety of treatment of esophageal cancer with trimodality therapy in patients’ ≥ 75 years were investigated in this retrospective review. They analyzed 570 cases (38 cases ≥75 years ) treated with trimodality therapy for esophageal cancer in 3 high volume tertiary cancer institutions from June 2007 to June 2013. At the time of diagnosis, 38 patients (7%) were 75 or older and had comorbidities including coronary artery disease (32%), atrial fibrillation (11%) and COPD (13%). About 87% of these patients received 50.4Gy/28 fractions. The most common chemotherapy regimen was 5-fluorouracil (5-FU)/cisplatin (37%), followed by 5-FU/docetaxel (24%). Outcomes support trimodality treatment as a reasonable approach for managing carefully selected elderly patients with esophageal cancer. With the therapy, these cases had similar rates of cancer outcomes, and treatment related morbidity and mortality as compared to younger patients.